Article Sidebar

Submitted
October 21, 2024
Accepted
October 21, 2024
Published
October 21, 2024
Download
PDF
Statistic
Read Counter : 445 Download : 287

Main Article Content

Abstract

Abstract: Toxoplasmosis is one of the most common diseases in the world. It is found all
over the world and affects a considerable proportion of people. It is known for being
asymptomatic and affects all warm-blodded animals, including humans. T. gondii parasite is
responsible for the disease. Patients with weakened immune systems, such as those with AIDS or
cancer, are most at risk for infection. The study's main goal is to detect T. gondii infection in BC
patients using the serological method (ELISA). This study involves measuring the T.gondi (IgG)
levels of 150 patients with breast cancer whom entered oncology center of Al-Haboubi Teaching
Hospital in Nasiriya City (southern Iraq ), and 54 healthy controls. The results demonstrated that
47.3% of breast cancer patients were infected with T. gondii compared with the control group
(33.3%). The age group with the highest infection rate was (41–50) years old among BC patients
infected with T.gondii (38%), while the age range between 71–80 years old had the lowest
infection rate (4%).Additionally, there was a higher rate of toxoplasmosis among patients with
breast cancer whom were lived in urban (57.75%) compared with those living in rural. The
results showed a high rate of breast cancer patients with toxoplasmosis (59.15%) in grade 2
compared with other grades. Stage III of breast cancer showed a high rate of infection with
toxoplasmosis (66.19%) compared with other stages

Keywords

Toxoplasmosis breast cancer serology histological grade

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004 Jan 17;363(9425):1965-76.
  2. doi:10.1016/S0140-6736(04)16412-X.
  3. Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN
  4. Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal
  5. for Clinicians, 71, 209-249 https://doi.org/10.3322/caac.21660.
  6. Dalimi A, Abdoli A. Latent toxoplasmosis and human. Iran J Parasitol. 2012;7(1):1.
  7. doi:10.1016/S0140-6736(04)16412-X.
  8. Abdoli A, Barati M, Dalimi A, Pirestani M, Hoseini Shokouh SJ. Toxoplasmosis among patients
  9. with immunocompromising conditions: a snapshot. J Arch MilMed.2016;4(4).DOI:
  10. https://doi.org/10.5812/jamm.41832
  11. Abdoli A. Neglected risk factors for HIV and Toxoplasma gondii co-infection. Lancet HIV.
  12. ;4(4). doi: 10.1016/S2352-3018(17)30054-8.
  13. Rasti S, Hassanzadeh M, Soliemani A, et al. Serological and molecular survey of toxoplasmosis
  14. in renal transplant recipients and hemodialysis patients in Kashan and Qom regions, Central Iran. Ren
  15. Fail. 2016;38(6):970-973. doi: 10.1080/0886022X.2016.1208987.
  16. Wang ZD, Liu HH, Ma ZX, et al. Toxoplasma gondii infection in immunocompromised patients:
  17. a systematic review and meta-analysis. Front Microbiol. 2017;8:8. doi: 10.3389/fmicb.2017.00008.
  18. Klastersky J, Aoun M. Opportunistic infections in patients with cancer. Ann Oncol. 2004;15. doi:
  19. 1093/annonc/mdh658.
  20. Khabaz MN, Elkhateeb L, Al-Alami J. Reactivation of latent Toxoplasma gondii in
  21. immunocompromised cancer patients. Comp Clin Pathol. 2011;20(2):183-186. doi: 10.1007/s00580-010-
  22. -0.
  23. Vietzke WM, Gelderman AH, Grimley PM, Valsamis MP. Toxoplasmosis complicating
  24. malignancy. Experience at the National Cancer Institute. Cancer. 1968;21(5):816-827. doi: 10.1002/1097-
  25. (196805)21:5<816::AID-CNCR2820210502>3.0.CO;2-N.
  26. Ernst DJ, Martel AM, Arbique JC, Ernst C, Johnson S, McCall RE. Collection of diagnostic
  27. venous blood specimens. Clin Lab Stand Inst [Internet]. 2017;37(7):1-60. Available from:
  28. https://doi.org/10.3336/clsi.2017.37.7.
  29. Dubey JP. Toxoplasmosis of Animals and Humans. CRC Press, Boca Raton, Florida; 2016.
  30. https://doi.org/10.1201/9781420092370
  31. Sudan V, Jaiswa AK, Shanker D. Recent trends in the diagnosis of toxoplasmosis. Clin Rev Opin.
  32. ;5:11-17.DOI: 10.5897/CRO11.022
  33. American Cancer Society. Breast Cancer: Treating Breast Cancer. American Cancer Society;
  34. p. 1-120.
  35. Anvari D, Sharif M, Sarvi S, et al. Seroprevalence of Toxoplasma gondii infection in cancer
  36. patients: a systematic review and meta-analysis. Microb Pathog. 2019;129:30-42. doi:
  37. 1016/j.micpath.2019.01.038.
  38. M. N. Khabaz, L. Elkhateeb, and J. Al-Alami, “Reactivation of latent toxoplasma gondii in
  39. immunocompromised cancer patients,” Comparative Clinical Pathology, vol. 20, no. 2, pp. 183–186,
  40. Wang L, He LY, Chen ZW, Wen H, Fang GS, Luo QL, Huang KQ, Shen JL. Seroprevalence and
  41. genetic characterization of Toxoplasma gondii in cancer patients in Anhui Province, Eastern China.
  42. Parasit Vectors. 2015;8(1):162. doi: 10.1186/s13071-015-0774-6.
  43. AL-Aboody BA, AL-Rekaby NKM. Prevalence of Toxoplasma gondii among
  44. immunocompromised patients (hemodialysis and cancer) in the province of Thi-Qar-Iraq. J Thi-Qar Sci.
  45. ;6(3) DOI: 10.32792/utq/utjsci/v6i3.41.
  46. Ali MI, Abd El Wahab WM, Hamdy DA, Hassan A. Toxoplasma gondii in cancer patients
  47. receiving chemotherapy: seroprevalence and interferon gamma level. J Parasit Dis. 2019;43(3):464-471.
  48. doi: 10.1007/s12639-019-01140-7.
  49. Haghbin M, Maani S, Bagherzadeh MA, Bazmjoo A, Shakeri H, Taghipour A, et al. Latent
  50. Toxoplasmosis among Breast Cancer Patients in Jahrom, South of Iran. Int J Breast Cancer. 2023. doi:
  51. 1155/2023/123456.
  52. Azab Hameed F, Khalaf AK. The effect of infection with Toxoplasma gondii in inducing
  53. interferon-gamma in breast cancer patients. Arch Razi Inst. 2024;79(1). DOI:
  54. 32592/ARI.2024.79.1.138.
  55. - Ghasemian M, Maraghi S, Saki J, Pedram M. Determination of antibodies (IgG, IgM) against
  56. Toxoplasma gondii in patients with cancer. Iran J Parasitol. 2007;2:1-6. doi:not available .
  57. Ahmed DF, Saheb EJ. Prevalence of Toxoplasmosis Infection in Iraqi Women with Different
  58. Types of Cancer. Diyala J Med. 2017;13(2):56-62.doi: 10.26505/DJM.19015290308
  59. Al-Tameemi IA, Abdullah BH, Raisan SJ. Seroprevalence of T. gondii among cancer patients in
  60. Basrah province/Iraq.DOI:10.20959/wjpr20191-13808
  61. Assim MM, Saheb EJ. The Association of Severe Toxoplasmosis and Some Cytokine Levels in
  62. Breast Cancer Patients. Iraqi J Sci. 2018:1189-1194. DOI:10.24996/ijs.2018.59.3A.6
  63. Sood R, Masalu N, Connolly RM, et al. Invasive breast Cancer treatment in Tanzania: landscape
  64. assessment to prepare for implementation of standardized treatment guidelines. BMC Cancer.
  65. ;21:527. doi: 10.1186/s12885-021-08310-9.
  66. Imam A, Al-Anzi FG, Al-Ghasham MA, Al-Suraikh MA, Al-Yahya AO, Rasheed Z. Serologic
  67. evidence of Toxoplasma gondii infection among cancer patients: A prospective study from Qassim
  68. region, Saudi Arabia. Saudi Med J. 2017 Mar;38(3):319. doi: 10.15537/smj.2017.3.17436.
  69. Kadhum B. Molecular diagnosis of Toxoplasma gondii in the tissue of breast cancer patients in
  70. Thi-Qar province. 2023. doi: 10.21203/rs.3.rs-189634/v1.
  71. Anvari D, Sharif M, Sarvi S, et al. Seroprevalence of Toxoplasma gondii infection in cancer
  72. patients: A systematic review and meta-analysis. Microb Pathog. 2019 Apr;129:30-42. doi:
  73. 1016/j.micpath.2019.01.033

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)